Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Acute Lymphoblastic Leukemia — Treatment

First-line Second-line SECOND-LINE Acute lymphoblastic leukemia (ALL) Ph+ (BCR::ABL1) Ph− B-cell T-cell ALL Relapsed / refractory B-ALL TKI-based TKI + chemo PhALLCON ↗ Chemo-sparing TKI + blinatumomab D-ALBA ↗ AYA Pediatric-inspired chemo CALGB 10403 ↗ MRD+ Add blinatumomab BLAST ↗ Chemo Multiagent ± nelarabine T-ALL ↗ BiTE Blinatumomab TOWER ↗ ADC Inotuzumab ozogamicin INO-VATE ↗ Cellular CD19 CAR-T tisagenlecleucel / brexu-cel ↗